Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Chembio Diagnostics has signed an exclusive development agreement with Bio-Rad Laboratories, to develop a multiplex test employing Chembio's patented DPP Dual Path Platform test system.
Subscribe to our email newsletter
The test would also employ certain proprietary reagents belonging to Bio-Rad. The agreement contemplates that the parties would enter into a limited exclusive license to the DPP technology. Bio-Rad would have exclusive marketing rights for the product.
Larry Siebert, Chembio’s CEO, said: “This collaboration with a world market leader like Bio-Rad is a good fit for Chembio, as it allows us to leverage our DPP intellectual property with our experience in product development and regulated manufacturing to develop a product to be marketed by a leading diagnostics company.”